PTC Therapeutics Stock News

SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi�

The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two mo

SOUTH PLAINFIELD, N.J., March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ (risdi

Edgewise Therapeutics has filed to raise $150 million in an IPO.

SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in child

SOUTH PLAINFIELD, N.J., March 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Be

SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CH

PTC Therapeutics, Inc (PTCT) CEO Stuart Peltz on Q4 2020 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -20.00% and 4.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

SOUTH PLAINFIELD, N.J., Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided

SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evalu

SOUTH PLAINFIELD, N.J., Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translar

Risk~reward tradeoffs and net payoffs offered by this group are better than those of most S&P 500 Index stocks and of most other Market-Maker [MM] forecast securities. They also outdo the prospects of

SOUTH PLAINFIELD, N.J., Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of

SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare